Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study

被引:12
作者
Chen, Zhen-Ping [1 ]
Li, Pei-Jing [1 ]
Li, Gang [1 ]
Tang, Ling [1 ]
Zhen, Ying-Zi [1 ]
Wu, Xin-Yi [1 ]
Cheng, Xiao-Ling [1 ]
Luke, Koon Hung [2 ,3 ,4 ]
Blanchette, Victor S. [5 ]
Poon, Man-Chiu [6 ,7 ,8 ]
Ding, Qiu-Lan [9 ]
Wu, Run-Hui [1 ]
机构
[1] Capital Med Univ, Natl Key Discipline Pediat, Beijing Key Lab Pediat Hematol Oncol, Hematol Oncol Ctr,Beijing Childrens Hosp,Minist E, Beijing 100045, Peoples R China
[2] Childrens Hosp Eastern Ontario, Dept Pediat & Lab Med, Ottawa, ON K1H 8L1, Canada
[3] Childrens Hosp Eastern Ontario, Hemophilia Clin, Ottawa, ON K1H 8L1, Canada
[4] Univ Ottawa, Ottawa, ON K1H 8L1, Canada
[5] Univ Toronto, Res Inst, Hosp Sick Children, Dept Pediat & Child Hlth Evaluat Sci,Div Hematol, Toronto, ON M5G 1X8, Canada
[6] Univ Calgary, Foothills Hosp, Dept Med Pediat & Oncol, Calgary, AB T2N 2T9, Canada
[7] Univ Calgary, Foothills Hosp, Southern Alberta Rare Blood & Bleeding Disorders, Calgary, AB T2N 2T9, Canada
[8] Calgary Hlth Reg, Calgary, AB T2N 2T9, Canada
[9] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Lab Med, Sch Med, Shanghai 200025, Peoples R China
关键词
Boys; Factor VIII; Hemophilia A; Pharmacokinetics; DOSE SECONDARY PROPHYLAXIS; RECOMBINANT FACTOR-VIII; HALF-LIFE; FVIII; CHILDREN; RECOVERY; EFFICACY; PLASMA;
D O I
10.4103/0366-6999.233604
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Although much attention has been paid to the pharmacokinetics (PKs) of different factor VIII (FVIII) concentrates in persons with hemophilia A (HA), limited information is available in young boys with severe HA. In this study, we aimed to assess the PK parameters of FVIII products in boys with severe HA in China. Methods: A total of 36 boys (plasma-derived [pd]-FVIII, n = 15; recombinant [r] FVIII, n = 21) were enrolled between January 2015 and May 2016 in Beijing Children's Hospital. PK characteristics of FVIII products were studied according to a reduced 4-sampling time point design (1 h, 9 h, 24 h, and 48 h postinfusion). Results: The mean FVIII half-life (t(1/2)) was 10.99 +/- 3.45 h (range 5.52-20.02 h), the mean in vivo recovery (IVR) was 2.01 +/- 0.42 IU/dl per rU/kg (range 1.24-3.02 IU/l per IU/kg) and mean clearance (CL) of FVIII is 4.34 +/- 1.58 ml'kg(-1) h(-1) (range 2.29-7.90 ml.kg(-1) h(-1)). We also analyzed the influence of several parameters that potentially modulate FVIII PK. The age was closely associated with FVIII half-life (R-2 = 0.32, P < 0.01). The t(1/2) of FVIII increased by 0.59 h per year. Besides age, von Willebrand factor antigen (VWF: Ag) also was associated with FVIII half-life (R-2 = 0.52, P < 0.01). Patients with blood Group O had a shorter FVIII half-life than patients with non-O blood group (9.40 +/- 0.68 h vs. 12.3 +/- 0.79 h, t = 2.70, P = 0.01). The FVIII IR correlated with age (R-2 = 0.21, P < 0.01) and VWF: Ag level (R-2 = 0.28, P < 0.01). CL rates were faster in young patients and in those with low-VWF: Ag levels. CL rates of FVIII are higher in blood Group O versus non-blood Group O persons (5.02 +/- 0.38 vs. 4.00 +/- 0.32 ml.kg(-1) h(-1), t = 2.53, P = 0.02). Conclusions: Chinese boys with severe HA have similar PK values to other ethnic groups and large differences in FVIII PK between individual patients. Age, blood group, and VWF: Ag levels are important determining factors for FVIII CL.
引用
收藏
页码:1781 / U28
页数:6
相关论文
共 50 条
  • [41] Novel Severe Hemophilia A Mouse Model with Factor VIII Intron 22 Inversion
    Han, Jeong Pil
    Song, Dong Woo
    Lee, Jeong Hyeon
    Lee, Geon Seong
    Yeom, Su Cheong
    BIOLOGY-BASEL, 2021, 10 (08):
  • [42] Pharmacokinetics of Factor VIII in Adults with Hemophilia: A 24-Hour Single-Sample Study Focused on Trough Levels
    Zavala, Erendira Pacheco
    Rangel, Juan Sebastian Flores
    Avila, Luis Alexis Ramirez
    Vazquez, Marcos Javier Romero
    Sanchez, Veronica Zendejas
    Oliva, Carlos Vargas
    Villegas, Octavio Martinez
    Medina, Lauro Fabian Amador
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2025,
  • [43] Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A
    Oldenburg, Johannes
    Chambost, Herve
    Liu, Hai
    Hawes, Charles
    You, Xiaojun
    Yang, Xinqun
    Newman, Vanessa
    Robinson, Tara M.
    Hatswell, Anthony J.
    Hinds, David
    Santos, Sandra
    Ozelo, Margareth
    ADVANCES IN THERAPY, 2024, 41 (06) : 2267 - 2281
  • [44] Inversions of the factor VIII gene in Japanese patients with severe hemophilia A
    Fukuda, K
    Naka, H
    Morichika, S
    Shibata, M
    Tanaka, I
    Shima, M
    Yoshioka, A
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2004, 79 (03) : 303 - 306
  • [45] Mutation analysis of factor VIII in Korean patients with severe hemophilia A
    Chur-Woo You
    Hee-Sook Son
    Hee Jin Kim
    Eui-Jeon Woo
    Soon-Ae Kim
    Haing-Woon Baik
    International Journal of Hematology, 2010, 91 : 784 - 791
  • [46] Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States
    Neufeld, Ellis J.
    Sidonio, Robert F., Jr.
    O'Day, Ken
    Runken, M. Chris
    Meyer, Kellie
    Spears, Jeffrey
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (08) : 762 - 769
  • [47] Inversions of the Factor VIII Gene in Japanese Patients with Severe Hemophilia A
    Kazuyoshi Fukuda
    Hiroyuki Naka
    Shogo Morichika
    Masaru Shibata
    Ichiro Tanaka
    Midori Shima
    Akira Yoshioka
    International Journal of Hematology, 2004, 79 : 303 - 306
  • [48] Mutation analysis of factor VIII in Korean patients with severe hemophilia A
    You, Chur-Woo
    Son, Hee-Sook
    Kim, Hee Jin
    Woo, Eui-Jeon
    Kim, Soon-Ae
    Baik, Haing-Woon
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 91 (05) : 784 - 791
  • [49] A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A
    Bolon-Larger, Magali
    Chamouard, Valerie
    Bressolle, Francoise
    Boulieu, Roselyne
    THERAPEUTIC DRUG MONITORING, 2007, 29 (01) : 20 - 26
  • [50] Reduced-intensity, risk factor-stratified immunosuppression for acquired hemophilia A: single-center observational study
    Dobbelstein, Christiane
    Moschovakis, Georgios Leandros
    Tiede, Andreas
    ANNALS OF HEMATOLOGY, 2020, 99 (09) : 2105 - 2112